secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001171843-24-002453
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus reports Q1 2024 net loss of $17.9M, cash runway extended to Q2 2026
---------------------------------------------------------------------------

- Net loss $17.9M ($0.10 per share); revenue $1.5M, down from $6.7M YoY due to lower license and royalty revenue.
- Cash, equivalents & marketable securities $137.9M; expects cash runway through Q2 2026.
- End-of-treatment data for two Phase 2a imdusiran trials to be presented at EASL June 2024.
- AB-101 oral PD-L1 inhibitor Part 1 showed dose-dependent receptor occupancy; moving to multiple-ascending dose part.
- Favorable claim construction ruling in Moderna LNP lawsuit; trial set for April 21, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324002453/0001171843-24-002453-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184324002453/f8k_050224.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-002453

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer